ECSP066555A - Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina - Google Patents

Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina

Info

Publication number
ECSP066555A
ECSP066555A EC2006006555A ECSP066555A ECSP066555A EC SP066555 A ECSP066555 A EC SP066555A EC 2006006555 A EC2006006555 A EC 2006006555A EC SP066555 A ECSP066555 A EC SP066555A EC SP066555 A ECSP066555 A EC SP066555A
Authority
EC
Ecuador
Prior art keywords
inhibitors
reabsortion
norepinefrine
morfoline
derivatives
Prior art date
Application number
EC2006006555A
Other languages
English (en)
Inventor
Gordon Iain Campbell
Manuel Javier Cases-Thomas
Teresa Man
John Joseph Masters
Helene Catherine Eugenie Rudyk
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP066555A publication Critical patent/ECSP066555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula general (I)como inhibidores de la reabsorción de norepinefrina. Como tales, pueden también ser útiles para el tratamiento de trastornos del sistema nervioso central y/o periférico.
EC2006006555A 2003-11-10 2006-05-09 Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina ECSP066555A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326148.4A GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives
US53545904P 2004-01-09 2004-01-09

Publications (1)

Publication Number Publication Date
ECSP066555A true ECSP066555A (es) 2006-10-17

Family

ID=29726235

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006555A ECSP066555A (es) 2003-11-10 2006-05-09 Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina

Country Status (33)

Country Link
US (1) US7423037B2 (es)
EP (2) EP2223916A1 (es)
JP (1) JP4850068B2 (es)
KR (1) KR100783855B1 (es)
CN (1) CN1878762B (es)
AR (1) AR046927A1 (es)
AT (1) ATE478057T1 (es)
AU (1) AU2004289616B2 (es)
BR (1) BRPI0415273B8 (es)
CA (1) CA2544649C (es)
CR (1) CR8390A (es)
CY (1) CY1110796T1 (es)
DE (1) DE602004028750D1 (es)
DK (1) DK1682523T3 (es)
EA (1) EA009960B1 (es)
EC (1) ECSP066555A (es)
ES (1) ES2348872T3 (es)
GB (1) GB0326148D0 (es)
HR (1) HRP20100476T1 (es)
IL (1) IL175365A (es)
MA (1) MA28330A1 (es)
MY (1) MY141048A (es)
NO (1) NO336268B1 (es)
NZ (1) NZ546067A (es)
PE (1) PE20050491A1 (es)
PL (1) PL1682523T3 (es)
PT (1) PT1682523E (es)
SI (1) SI1682523T1 (es)
SV (1) SV2006001934A (es)
TW (1) TWI339658B (es)
UA (1) UA85198C2 (es)
WO (1) WO2005047272A1 (es)
ZA (1) ZA200603680B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399557T1 (de) * 2003-12-12 2008-07-15 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
RU2613633C1 (ru) * 2016-03-09 2017-03-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность
GB201915753D0 (en) * 2019-10-30 2019-12-11 Univ Warwick Alzheimer's disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
NL108827C (es) 1956-04-09
GB895309A (en) 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3141823A (en) 1962-09-04 1964-07-21 Res Lab Dr C Janssen N V Method for producing analgesia
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1999015177A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IL137346A0 (en) * 1998-01-21 2001-07-24 Glaxo Group Ltd Pharmaceutically active morpholinol
US6316444B1 (en) * 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
DE60035232T2 (de) * 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
GB0120461D0 (en) * 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
FR2852954B1 (fr) * 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
NO336268B1 (no) 2015-07-06
US7423037B2 (en) 2008-09-09
HRP20100476T1 (hr) 2010-10-31
GB0326148D0 (en) 2003-12-17
BRPI0415273A (pt) 2006-12-19
CN1878762A (zh) 2006-12-13
EP2223916A1 (en) 2010-09-01
BRPI0415273B8 (pt) 2021-05-25
CR8390A (es) 2007-12-07
PE20050491A1 (es) 2005-08-24
KR20060086408A (ko) 2006-07-31
MA28330A1 (fr) 2006-12-01
UA85198C2 (ru) 2009-01-12
ZA200603680B (en) 2007-07-25
PT1682523E (pt) 2010-09-20
DE602004028750D1 (de) 2010-09-30
AU2004289616A1 (en) 2005-05-26
ATE478057T1 (de) 2010-09-15
CA2544649A1 (en) 2005-05-26
CY1110796T1 (el) 2015-06-10
IL175365A0 (en) 2006-09-05
TW200524885A (en) 2005-08-01
SI1682523T1 (sl) 2010-12-31
JP4850068B2 (ja) 2012-01-11
ES2348872T3 (es) 2010-12-16
NZ546067A (en) 2009-04-30
EP1682523B1 (en) 2010-08-18
EP1682523A1 (en) 2006-07-26
EA200600945A1 (ru) 2006-10-27
WO2005047272A1 (en) 2005-05-26
SV2006001934A (es) 2006-02-15
BRPI0415273B1 (pt) 2019-04-30
US20070083046A1 (en) 2007-04-12
CA2544649C (en) 2012-08-14
DK1682523T3 (da) 2010-11-15
JP2007510720A (ja) 2007-04-26
KR100783855B1 (ko) 2007-12-10
HK1095135A1 (en) 2007-04-27
AR046927A1 (es) 2006-01-04
EA009960B1 (ru) 2008-04-28
NO20062700L (no) 2006-08-08
PL1682523T3 (pl) 2011-01-31
MY141048A (en) 2010-02-25
TWI339658B (en) 2011-04-01
AU2004289616B2 (en) 2010-08-05
IL175365A (en) 2011-02-28
CN1878762B (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
CY1108230T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
UY28144A1 (es) Agentes terapéuticos
EA200700909A1 (ru) Азаиндолкарбоксамиды
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
UY31326A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
GB0525069D0 (en) Organic compounds
ECSP066555A (es) Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
ATE534638T1 (de) Piperazin-derivate
UA94054C2 (en) Nitrocatechol derivatives as comt inhibitors
UY29078A1 (es) Amidas del ácido 5 y 6-aminoalquil indol-2-carboxílico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon)
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
DOP2004001025A (es) Derivados de morfolina como inhibidores de la recaptacion de norepinefrina
TW200616637A (en) Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы